Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

“KarXT是继20世纪50年代初第一代抗精神病药氯丙嗪诞生后，首款采用全新作用机制的抗精神病药物，两者相差70年左右。KarXT的获批有望为精神分裂症患者带来更多治疗选择。”9月27日，北京回龙观医院精神科主任医师陈松告诉人民日报健康客户端记者。

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

The Food and Drug Administration on Thursday approved the first novel antipsychotic treatment in decades, a drug developed to ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia.

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...